Broken drug markets in infectious diseases: Opportunities outside the private sector?

Jonathan D. Alpern, Stephen J. Dunlop, William M. Stauffer

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution.

Original languageEnglish (US)
Article numbere0007190
JournalPLoS neglected tropical diseases
Volume13
Issue number4
DOIs
StatePublished - Apr 2019

Keywords

  • Anti-Infective Agents/economics
  • Communicable Diseases/drug therapy
  • Drug Industry/economics
  • Drugs, Generic/economics
  • Humans
  • Prescription Drugs/economics
  • Public Sector
  • United States
  • United States Food and Drug Administration

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Broken drug markets in infectious diseases: Opportunities outside the private sector?'. Together they form a unique fingerprint.

Cite this